Some therapies for psoriasis, PSA linked to HBV, HCV reactivation
A 15-year study recommends taking into consideration the differential risks of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivations when choosing targeted therapies for the treatment of psoriasis and psoriatic arthritis (PsA), particularly in patients with risk factors for viral reactivation.
Some therapies for psoriasis, PSA linked to HBV, HCV reactivation
16 Feb 2026